MannKind's Inhalable Insulin Will Not Be Available This Year
October 06, 2009 at 14:29 PM EDT
MannKind Corp. (Nasdaq: MNKD) blamed regulatory delays for announcing that its inhalable insulin product Afresca will not be available at the end of the year. The stock price plunged $2.70 to $6.51.
